MX376190B - PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO. - Google Patents

PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.

Info

Publication number
MX376190B
MX376190B MX2016012201A MX2016012201A MX376190B MX 376190 B MX376190 B MX 376190B MX 2016012201 A MX2016012201 A MX 2016012201A MX 2016012201 A MX2016012201 A MX 2016012201A MX 376190 B MX376190 B MX 376190B
Authority
MX
Mexico
Prior art keywords
encoding mir
raav particles
particles encoding
viral particles
mir
Prior art date
Application number
MX2016012201A
Other languages
English (en)
Spanish (es)
Other versions
MX2016012201A (es
Inventor
Catherine O´Riordan
Matthew Adamowicz
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX376190(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2016012201A publication Critical patent/MX2016012201A/es
Publication of MX376190B publication Critical patent/MX376190B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016012201A 2014-03-21 2015-03-20 PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO. MX376190B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21
PCT/US2015/021896 WO2015143418A2 (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Publications (2)

Publication Number Publication Date
MX2016012201A MX2016012201A (es) 2017-01-19
MX376190B true MX376190B (es) 2025-03-07

Family

ID=52829343

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012201A MX376190B (es) 2014-03-21 2015-03-20 PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.
MX2020010694A MX2020010694A (es) 2014-03-21 2016-09-20 Particulas de raav que codifican mir-708 y usos del mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010694A MX2020010694A (es) 2014-03-21 2016-09-20 Particulas de raav que codifican mir-708 y usos del mismo.

Country Status (36)

Country Link
US (3) US10383953B2 (OSRAM)
EP (3) EP4345165A3 (OSRAM)
JP (3) JP6669664B2 (OSRAM)
KR (3) KR20160127832A (OSRAM)
CN (2) CN106456660B (OSRAM)
AR (1) AR099837A1 (OSRAM)
AU (3) AU2015230942B2 (OSRAM)
CA (2) CA2943185C (OSRAM)
CL (1) CL2016002333A1 (OSRAM)
CR (1) CR20160480A (OSRAM)
DK (2) DK3119437T3 (OSRAM)
DO (1) DOP2016000237A (OSRAM)
EA (1) EA201691891A1 (OSRAM)
EC (1) ECSP16083000A (OSRAM)
ES (2) ES2760263T3 (OSRAM)
FI (1) FI3628334T3 (OSRAM)
HR (2) HRP20231077T1 (OSRAM)
HU (2) HUE046454T2 (OSRAM)
IL (3) IL247543B (OSRAM)
LT (2) LT3628334T (OSRAM)
MA (1) MA39390B2 (OSRAM)
MX (2) MX376190B (OSRAM)
MY (2) MY190726A (OSRAM)
NZ (1) NZ724622A (OSRAM)
PE (1) PE20161252A1 (OSRAM)
PH (1) PH12016501684B1 (OSRAM)
PL (2) PL3628334T3 (OSRAM)
PT (2) PT3119437T (OSRAM)
RS (2) RS59634B1 (OSRAM)
SG (3) SG10201912968WA (OSRAM)
SI (2) SI3119437T1 (OSRAM)
TW (2) TWI780401B (OSRAM)
UA (1) UA120050C2 (OSRAM)
UY (1) UY36044A (OSRAM)
WO (1) WO2015143418A2 (OSRAM)
ZA (1) ZA201605924B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3119437T (pt) 2014-03-21 2019-12-12 Genzyme Corp Terapia genética para retinopatia pigmentar
EA201791805A1 (ru) 2015-02-10 2018-05-31 Джензим Корпорейшн ВАРИАНТ СРЕДСТВА ДЛЯ RNAi
CN108474001B (zh) * 2015-12-03 2022-04-08 弗里德里克·米谢尔生物医学研究所 SynP160，用于基因在视杆光感受器中特异性表达的启动子
ES2886664T3 (es) 2015-12-03 2021-12-20 Friedrich Miescher Institute For Biomedical Res SynP162, un promotor para la expresión específica de genes en fotorreceptores de bastón
CA3004807C (en) * 2015-12-04 2022-02-22 Universite Pierre Et Marie Curie (Paris 6) Promoters and uses thereof
CN109154002B (zh) * 2016-03-01 2022-08-30 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体
SG11201900049QA (en) * 2016-07-05 2019-02-27 Univ Johns Hopkins Crispr/cas9-based compositions and methods for treating retinal degenerations
JP7257377B2 (ja) * 2017-03-21 2023-04-13 ミヒャラキス，スティリアノス Ｃｎｇｂ１連鎖性網膜色素変性症の治療のための遺伝子療法
AU2018335410B2 (en) * 2017-09-22 2025-04-03 Genzyme Corporation Variant RNAi
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
US12162994B2 (en) 2018-03-02 2024-12-10 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
EP3768327A4 (en) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
WO2019232517A1 (en) * 2018-06-01 2019-12-05 University Of Florida Research Foundation, Incorporated Compositions and methods for treatment of dominant retinitis pigmentosa
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
US20220143217A1 (en) * 2019-03-04 2022-05-12 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway
KR20210145180A (ko) * 2019-03-21 2021-12-01 피티씨 테라퓨틱스, 인크. 엔젤만 증후군을 치료하기 위한 벡터 및 방법
US20220288101A1 (en) * 2019-08-15 2022-09-15 The Children's Hospital Of Philadelphia Combined transgene and intron-derived mirna therapy for treatment of sca1
WO2021142447A1 (en) * 2020-01-10 2021-07-15 Solid Biosciences Inc. Viral vector for combination therapy
MX2022009252A (es) * 2020-01-29 2022-11-09 Genzyme Corp Proteinas de la capside de virus adeno-asociados modificadas para la terapia genica ocular y metodos de uso de las mismas.
EP4071247A4 (en) * 2020-07-24 2023-08-23 Rznomics Inc. TRANSSPLICING OF RIBOZYME SPECIFIC TO RHODOPSIN TRANSCRIPTOME AND ITS USE
EP4188450A2 (en) * 2020-07-29 2023-06-07 University Of Florida Research Foundation, Incorporated Improved aav-mediated x-linked retinoschisis therapies
EP4323390A1 (en) * 2021-04-16 2024-02-21 Regeneron Pharmaceuticals, Inc. Treatment of x-linked juvenile retinoschisis
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途
CN120098992A (zh) * 2023-12-05 2025-06-06 云舟生物科技(广州)股份有限公司 核酸分子及其作为特异启动子的应用
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
CA2410828C (en) 2000-06-01 2012-01-24 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
MX346493B (es) 2001-11-13 2017-03-21 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP2434020B1 (en) * 2004-01-22 2014-11-05 Dnavec Research Inc. Method of producing Paramyxoviridae viral vectors using a hybrid promoter comprising a cytomegalovirus enhancer and a chicken beta-actin promoter
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2140004B1 (en) * 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
US20090214478A1 (en) 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CN102573856B (zh) * 2009-09-10 2016-10-26 弗莱明·韦林 用于制备微小rna 的方法及其治疗性应用
CN102947453A (zh) 2010-01-28 2013-02-27 费城儿童医院 用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
GB2537000C (en) * 2012-05-25 2019-10-09 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
EP2872183B1 (en) 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
WO2014066498A1 (en) * 2012-10-23 2014-05-01 Vivek Mittal Treatment of metastatic breast cancer
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
PT3119437T (pt) * 2014-03-21 2019-12-12 Genzyme Corp Terapia genética para retinopatia pigmentar

Also Published As

Publication number Publication date
JP2022084810A (ja) 2022-06-07
EP3119437A2 (en) 2017-01-25
IL284741B (en) 2022-10-01
ECSP16083000A (es) 2017-02-24
EP3628334B1 (en) 2023-06-28
US10383953B2 (en) 2019-08-20
IL247543B (en) 2020-07-30
AU2021200988A1 (en) 2021-03-11
KR20160127832A (ko) 2016-11-04
ES2760263T3 (es) 2020-05-13
DK3628334T3 (da) 2023-10-02
DK3628334T5 (da) 2024-09-02
IL275918A (en) 2020-08-31
TW202021627A (zh) 2020-06-16
PT3628334T (pt) 2023-09-26
ZA201605924B (en) 2017-09-27
MA39390A1 (fr) 2017-12-29
NZ724622A (en) 2022-05-27
SI3119437T1 (sl) 2020-01-31
SI3628334T1 (sl) 2023-11-30
AU2015230942A1 (en) 2016-10-13
MX2020010694A (es) 2020-11-06
PL3628334T3 (pl) 2023-12-18
EP3119437B1 (en) 2019-09-04
MY203654A (en) 2024-07-11
UY36044A (es) 2015-10-30
DOP2016000237A (es) 2016-10-16
US12201698B2 (en) 2025-01-21
PT3119437T (pt) 2019-12-12
JP7534348B2 (ja) 2024-08-14
PH12016501684A1 (en) 2016-10-03
PL3119437T3 (pl) 2020-04-30
LT3119437T (lt) 2019-12-27
KR20230006039A (ko) 2023-01-10
BR112016021017A2 (pt) 2017-10-03
SG11201607005UA (en) 2016-09-29
ES2957840T3 (es) 2024-01-26
AU2021200988B2 (en) 2024-08-01
CA3254798A1 (en) 2025-12-01
EP4345165A2 (en) 2024-04-03
AR099837A1 (es) 2016-08-24
TWI780401B (zh) 2022-10-11
MA39390B2 (fr) 2022-04-29
CA2943185A1 (en) 2015-09-24
WO2015143418A2 (en) 2015-09-24
PH12016501684B1 (en) 2023-03-17
US20170173183A1 (en) 2017-06-22
CL2016002333A1 (es) 2017-05-26
HUE046454T2 (hu) 2020-03-30
PE20161252A1 (es) 2016-11-30
MY190726A (en) 2022-05-12
JP7048563B2 (ja) 2022-04-05
WO2015143418A3 (en) 2015-11-19
KR20250172735A (ko) 2025-12-09
HRP20192141T1 (hr) 2020-02-21
IL275918B (en) 2021-07-29
SG10201808218YA (en) 2018-10-30
MX2016012201A (es) 2017-01-19
AU2024227776A1 (en) 2024-11-28
CN106456660B (zh) 2022-05-31
US20200046851A1 (en) 2020-02-13
JP2017509632A (ja) 2017-04-06
EP3628334A1 (en) 2020-04-01
IL284741A (en) 2021-08-31
AU2015230942B2 (en) 2020-11-19
HRP20231077T1 (hr) 2023-12-22
CN115252823A (zh) 2022-11-01
EA201691891A1 (ru) 2017-01-30
CA2943185C (en) 2025-09-16
RS64611B1 (sr) 2023-10-31
JP6669664B2 (ja) 2020-03-18
RS59634B1 (sr) 2020-01-31
HUE063460T2 (hu) 2024-01-28
IL284741B2 (en) 2023-02-01
DK3119437T3 (da) 2019-12-09
FI3628334T3 (fi) 2023-09-15
UA120050C2 (uk) 2019-09-25
TW201622752A (zh) 2016-07-01
NZ762841A (en) 2023-11-24
LT3628334T (lt) 2023-09-25
CR20160480A (es) 2016-12-14
JP2020059737A (ja) 2020-04-16
US20220054657A1 (en) 2022-02-24
SG10201912968WA (en) 2020-02-27
TWI706789B (zh) 2020-10-11
US11103598B2 (en) 2021-08-31
CN106456660A (zh) 2017-02-22
EP4345165A3 (en) 2024-09-25
IL247543A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MX376190B (es) PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MY187540A (en) Compounds active towards bromodomains
EP4094780A3 (en) Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
ZA201701881B (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
MX378098B (es) Derivados de piperazina como moduladores de ror?.
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
MX2017014257A (es) Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
BR112017012931A2 (pt) métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos
IT201600069689U1 (it) Benda elastica, particolarmente per l’impiego nel trattamento del flebo-linfoedema.
RU2014148879A (ru) Способы воздействия на экспрессию гена PRP
RU2014145910A (ru) Способы воздействия на экспрессию гена APOE

Legal Events

Date Code Title Description
FG Grant or registration